What are the long-term outcomes of iliac-vein stenting in young patients (under 45 years) with May-Thurner syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Long-Term Iliac Vein Stent Outcomes in Young May-Thurner Patients

Iliac vein stenting for May-Thurner syndrome in young patients demonstrates excellent long-term durability with primary patency rates of 84-93% at 2-3 years and secondary patency exceeding 95%, making it the definitive treatment when combined with thrombolysis for acute DVT or as standalone therapy for chronic venous obstruction. 1, 2

Evidence for Long-Term Patency

The data specifically addressing young patients is robust and reassuring:

  • In adolescents and young adults (ages 12-20 years), primary patency at 24 months reaches 88.9% for non-thrombotic lesions and 84.4% for thrombotic presentations, with overall patency (including reinterventions) of 95.4% and 96.9% respectively. 2

  • Technical success rates exceed 98% in young patients, with clinical symptom improvement achieved in 93-94% of cases. 2

  • The 3-year data from large series show sustained symptom relief, with 79% maintaining pain reduction and 66% maintaining swelling reduction at 3 years. 3

Critical Age-Related Considerations

Young patients warrant special attention because:

  • Patients under 50 years presenting with claudication or venous symptoms may have more aggressive disease, but venous stenting outcomes remain excellent—unlike arterial interventions which perform worse in this age group. 4

  • Young, otherwise healthy patients with acute left-sided DVT should immediately raise suspicion for May-Thurner syndrome, as anatomic compression is more prevalent in this population. 1

  • The anatomic compression persists despite anticoagulation alone, making mechanical relief essential to prevent recurrent VTE. 1

Treatment Algorithm for Young Patients

Acute Presentation (DVT <14 days):

  • Initiate therapeutic anticoagulation immediately with unfractionated heparin or LMWH. 1

  • Perform catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy (PMT) to remove thrombus burden before stenting (Class IIa recommendation). 3, 1

  • Pharmacomechanical thrombectomy reduces thrombolytic drug dose by 40-50% and shortens infusion time compared to CDT alone. 1

  • After thrombus removal, perform balloon angioplasty followed by self-expanding stent placement—angioplasty alone typically fails. 1

Non-Thrombotic or Chronic Presentation:

  • Proceed directly to venography with intravascular ultrasound (IVUS) to confirm >50% stenosis. 5

  • Stent placement without preceding thrombolysis achieves 83-98% anatomic success for chronically occluded iliac veins. 3

  • This approach significantly improves quality of life scores and enables venous ulcer healing in 56% of affected patients. 3

Technical Specifications

  • Confine stents to the iliac vein whenever feasible to optimize patency. 3

  • If the lesion extends into the common femoral vein, caudal stent extension is reasonable but expect modestly reduced patency (90% vs 84%). 3

  • Self-expanding bare-metal stents are the standard choice, with average sizes ranging 12-16mm depending on vessel diameter. 2, 5

Post-Stenting Management for Young Patients

Anticoagulation Protocol:

  • Continue therapeutic anticoagulation with the same dosing, monitoring, and duration as iliofemoral DVT patients without stents—minimum 3 months, indefinite for unprovoked events. 3, 1

  • Direct oral anticoagulants are preferred over warfarin in non-cancer patients due to lower bleeding risk. 1

  • Add antiplatelet therapy to anticoagulation in high-risk patients (poor inflow, suboptimal result) after individualized bleeding assessment. 3

Compression Therapy:

  • Prescribe 30-40 mmHg knee-high elastic compression stockings for at least 2 years to reduce post-thrombotic syndrome risk. 1

Timing of Complications

A critical finding for counseling young patients:

  • When stent complications occur, they manifest early—within the first year, particularly within the first 4 months. 6

  • If initial luminal patency is achieved, it remains well-maintained during long-term follow-up with no new in-stent stenosis developing after the first year. 6

  • Stent fracture is rare (~1% of cases) and can be successfully managed with a second stent when it occurs. 3

Special Situations in Young Patients

Pregnancy Considerations:

  • In 62 women with left iliac vein stents who later became pregnant and received LMWH prophylaxis, zero experienced recurrent VTE during pregnancy or postpartum. 3

  • Mechanical stent deformation may occur on duplex ultrasound late in pregnancy but resolves spontaneously postpartum without clinical sequelae. 3

Limb-Threatening Presentation:

  • For phlegmasia cerulea dolens, CDT or PCDT is a Class I (mandatory) recommendation—anticoagulation alone is inadequate and risks limb loss. 1

Common Pitfalls to Avoid

  • Do not rely on anticoagulation alone when May-Thurner is identified; the persistent anatomic compression predisposes to recurrent VTE regardless of anticoagulation adequacy. 1

  • Do not delay endovascular intervention; early thrombus removal within 14 days yields optimal outcomes. 1

  • Do not dismiss symptoms in young patients as musculoskeletal—left-sided leg swelling in young women has 4.88 times higher odds of being May-Thurner compared to right-sided or male presentations. 5

  • Procedural bleeding complications during CDT are rare (1-4%), and thrombolysis-related bleeding is essentially absent with modern pharmacomechanical techniques. 2, 7

Surveillance Protocol

  • Perform duplex ultrasound at 3,6,12, and 24 months to evaluate venous patency and stent function. 8

  • CT venography can be used selectively for comprehensive evaluation of stent morphology and surrounding anatomy. 6

References

Guideline

Iliac Vein Stenting in Young Patients with May‑Thurner Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Outcomes of endovascular intervention for May-Thurner syndrome.

Journal of vascular surgery. Venous and lymphatic disorders, 2013

Guideline

Management of Extensive Left Leg DVT with AV Fistula

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.